Rankings
▼
Calendar
PTCT
PTC Therapeutics, Inc.
$5B
Q1 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$56M
+111.2% YoY
Gross Profit
$53M
94.6% margin
Operating Income
-$17M
-29.9% margin
Net Income
-$19M
-34.4% margin
EPS (Diluted)
$-0.46
QoQ Revenue Growth
-28.2%
Cash Flow
Operating Cash Flow
-$16M
Free Cash Flow
-$16M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$379M
Total Liabilities
$229M
Stockholders' Equity
$150M
Cash & Equivalents
$98M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$56M
$27M
+111.2%
Gross Profit
$53M
$27M
+100.0%
Operating Income
-$17M
-$26M
+36.5%
Net Income
-$19M
-$29M
+33.7%
Revenue Segments
Licensing And Collaboration Agreement
$100,000
100%
← FY 2018
All Quarters
Q2 2018 →
PTCT Q1 2018 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena